Skip to main content


Novel agents for cancer therapy

This Article Collection highlights research published in 2013-2015 on targeted inhibitor and other cancer therapies.

  1. Review

    Novel ALK inhibitors in clinical use and development

    Anaplastic lymphoma kinase 1 (ALK-1) is a member of the insulin receptor tyrosine kinase family. ALK-1 was initially found in anaplastic large cell lymphoma (ALCL). ALK mutations have also been implicated in t...

    Chaitanya Iragavarapu, Milaim Mustafa, Akintunde Akinleye, Muhammad Furqan, Varun Mittal, Shundong Cang and Delong Liu

    Journal of Hematology & Oncology 2015 8:17

    Published on: 27 February 2015

  2. Research highlight

    SWI/SNF proteins as targets in cancer therapy

    Recent identification of synthetic lethal interactions involving several proteins of the SWI/SNF complex discussed in this Research Highlight has opened the possibility of new cancer therapeutic approaches.

    Santiago Schiaffino-Ortega, Carlos Balinas, Marta Cuadros and Pedro P Medina

    Journal of Hematology & Oncology 2014 7:81

    Published on: 13 November 2014

  3. Review

    Strategies for modern biomarker and drug development in oncology

    Technological advancements in the molecular characterization of cancers have enabled researchers to identify an increasing number of key molecular drivers of cancer progression. These discoveries have led to m...

    Alan D Smith, Desam Roda and Timothy A Yap

    Journal of Hematology & Oncology 2014 7:70

    Published on: 3 October 2014

  4. Review

    New antibody approaches to lymphoma therapy

    The CD20-directed monoclonal antibody rituximab established a new era in lymphoma therapy. Since then other epitopes on the lymphoma surface have been identified as potential targets for monoclonal antibodies ...

    Tejas Suresh, Lisa X Lee, Jitesh Joshi and Stefan K Barta

    Journal of Hematology & Oncology 2014 7:58

    Published on: 9 September 2014

  5. Research

    Small-molecule survivin inhibitor YM155 enhances radiosensitization in esophageal squamous cell carcinoma by the abrogation of G2 checkpoint and suppression of homologous recombination repair

    Survivin is overexpressed in cancer cells and plays a crucial role in apoptosis evasion. YM155, a small-molecule inhibitor of survivin, could enhance the cytotoxicity of various DNA-damaging agents. Here, we e...

    Qin Qin, Hongyan Cheng, Jing Lu, Liangliang Zhan, Jianchao Zheng, Jing Cai, Xi Yang, Liping Xu, Hongcheng Zhu, Chi Zhang, Jia Liu, Jianxin Ma, Xizhi Zhang, Shengbin Dai and Xinchen Sun

    Journal of Hematology & Oncology 2014 7:62

    Published on: 20 August 2014

  6. Research

    A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies

    CD19 is a B cell lineage specific surface receptor whose broad expression, from pro-B cells to early plasma cells, makes it an attractive target for the immunotherapy of B cell malignancies. In this study we p...

    Caroline S Breton, Aimable Nahimana, Dominique Aubry, Julie Macoin, Pierre Moretti, Martin Bertschinger, Samuel Hou, Michel A Duchosal and Jonathan Back

    Journal of Hematology & Oncology 2014 7:33

    Published on: 14 April 2014

  7. Research

    Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses

    Romidepsin is a structurally unique, potent, bicyclic class 1 selective histone deacetylase inhibitor approved by the US Food and Drug Administration for the treatment of patients with cutaneous T-cell lymphom...

    Bertrand Coiffier, Barbara Pro, H Miles Prince, Francine Foss, Lubomir Sokol, Matthew Greenwood, Dolores Caballero, Franck Morschhauser, Martin Wilhelm, Lauren Pinter-Brown, Swaminathan Padmanabhan Iyer, Andrei Shustov, Tina Nielsen, Jean Nichols, Julie Wolfson, Barbara Balser…

    Journal of Hematology & Oncology 2014 7:11

    Published on: 23 January 2014

  8. Review

    STAT inhibitors for cancer therapy

    Signal Transducer and Activator of Transcription (STAT) proteins are a family of cytoplasmic transcription factors consisting of 7 members, STAT1 to STAT6, including STAT5a and STAT5b. STAT proteins are though...

    Muhammad Furqan, Akintunde Akinleye, Nikhil Mukhi, Varun Mittal, Yamei Chen and Delong Liu

    Journal of Hematology & Oncology 2013 6:90

    Published on: 5 December 2013

  9. Review

    Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics

    Phosphatidylinositol 3-kinases (PI3Ks) are lipid kinases that regulate diverse cellular processes including proliferation, adhesion, survival, and motility. Dysregulated PI3K pathway signaling occurs in one-th...

    Akintunde Akinleye, Parthu Avvaru, Muhammad Furqan, Yongping Song and Delong Liu

    Journal of Hematology & Oncology 2013 6:88

    Published on: 22 November 2013

  10. Review

    Ibrutinib and novel BTK inhibitors in clinical development

    Small molecule inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have significantly improved clinical outcomes in cancer patients. Recently Bruton’s tyrosine kinase (BTK), a cru...

    Akintunde Akinleye, Yamei Chen, Nikhil Mukhi, Yongping Song and Delong Liu

    Journal of Hematology & Oncology 2013 6:59

    Published on: 19 August 2013

  11. Review

    Signal transduction inhibitors in treatment of myelodysplastic syndromes

    Myelodysplastic syndromes (MDS) are a group of hematologic disorders characterized by ineffective hematopoiesis that results in reduced blood counts. Although MDS can transform into leukemia, most of the morbi...

    Lohith Bachegowda, Oleg Gligich, Ionnis Mantzaris, Carolina Schinke, Dale Wyville, Tatiana Carrillo, Ira Braunschweig, Ulrich Steidl and Amit Verma

    Journal of Hematology & Oncology 2013 6:50

    Published on: 10 July 2013

  12. Review

    Novel agents and biomarkers for acute lymphoid leukemia

    New genetic markers for adult acute lymphoblastic leukemia (ALL) have been found to have prognostic impact, such as the lymphoid transcription factor gene IKZF1 alterations, which are associated with a high ra...

    Yanmin Zhao, He Huang and Guoqing Wei

    Journal of Hematology & Oncology 2013 6:40

    Published on: 18 June 2013

  13. Review

    Targeted therapy for HER2 positive breast cancer

    Breast cancer is the second most common cause of death for women behind lung cancer and the most common cause of cancer deaths for women aged 45–55 years old ( 2012). Although there continue to be enorm...

    Jason A Incorvati, Shilpan Shah, Ying Mu and Janice Lu

    Journal of Hematology & Oncology 2013 6:38

    Published on: 3 June 2013

  14. Review

    B-Raf and the inhibitors: from bench to bedside

    The B-Raf protein is a key signaling molecule in the mitogen activated protein kinase (MAPK) signaling pathway and has been implicated in the pathogenesis of a variety of cancers. An important V600E mutation h...

    Tiangui Huang, Michael Karsy, Jian Zhuge, Minghao Zhong and Delong Liu

    Journal of Hematology & Oncology 2013 6:30

    Published on: 25 April 2013

  15. Review

    MEK and the inhibitors: from bench to bedside

    Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members of MEK family proteins. Several MEK inhibitors are in clinical trials. Trametin...

    Akintunde Akinleye, Muhammad Furqan, Nikhil Mukhi, Pavan Ravella and Delong Liu

    Journal of Hematology & Oncology 2013 6:27

    Published on: 12 April 2013

  16. Review

    Targeting p53 by small molecules in hematological malignancies

    p53 is a powerful tumor suppressor and is an attractive cancer therapeutic target. A breakthrough in cancer research came from the discovery of the drugs which are capable of reactivating p53 function. Most an...

    Manujendra N Saha, Lugui Qiu and Hong Chang

    Journal of Hematology & Oncology 2013 6:23

    Published on: 27 March 2013